Catalyst Biosciences Announces CFI Variant Presentations at Two Upcoming Scientific Conferences
October 29 2021 - 8:00AM
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that
Grant Blouse, Ph.D., chief scientific officer, will present at two
upcoming scientific conferences, the 5th Complement-based Drug
Development Summit, being held October 26-28, 2021, and the
American Society for Biochemistry and Molecular Biology’s (ASBMB)
Serine Proteases in Pericellular Proteolysis and Signaling Virtual
Meeting, being held October 28-30, 2021. Catalyst will provide an
overview of the Company’s ProTUNE™ platform, and its ability to
engineer Complement Factor I (CFI) for potency and specificity in
complement-mediated disorders.
"We are excited that the ProTUNE™ platform and specifically the
C3b/C4b degraders are demonstrating the potential to be used for
precision medicine, in multiple complement-related indications,”
said Grant Blouse, Ph.D., chief scientific officer of
Catalyst. “We’re looking forward to providing additional updates on
our complement discovery programs as well as on CB 4332, our
enhanced CFI protease for CFI deficiency expected to enter the
clinic in 2022.”
About Catalyst Biosciences, the Protease Medicines
companyCatalyst is a research and clinical development
biopharmaceutical company focused on addressing unmet medical needs
in rare disorders of the complement and coagulation systems. Our
protease engineering platform has generated two late-stage clinical
programs, including MarzAA, a subcutaneously (SQ) administered
next-generation engineered coagulation Factor VIIa (FVIIa) for the
treatment of episodic bleeding in subjects with rare bleeding
disorders. Our complement pipeline includes a preclinical
C3-degrader program licensed to Biogen for dry age-related macular
degeneration, CB 4332, an improved complement factor I protease for
SQ replacement therapy in patients with CFI deficiency, proteases
from our ProTUNE™ C3b/C4b degrader and ImmunoTUNE™ C3a/C5a degrader
platforms designed to target specific disorders of the complement
or inflammatory pathways, as well as other complement programs in
development.
Forward-Looking StatementsThis press release
contains forward-looking statements that involve substantial risks
and uncertainties. Forward-looking statements include, without
limitation, statements about the product candidates of Catalyst
Biosciences, Inc. (the “Company”) and the benefits of its protease
engineering platform; the potential markets for and advantages of
the Company's complement product candidates, including C3b and C4b
degraders; the ability of the ProTUNE™ platform to generate these
or other product candidates; and the potential for C3b and C4b
degraders to treat human disease, and expectations that CB 4332
will enter the clinic in 2022. Actual results or events could
differ materially from the plans, intentions, expectations and
projections disclosed in the forward-looking statements. Various
important factors could cause actual results or events to differ
materially, including, but not limited to, the risk that
preclinical or clinical studies may be delayed as a result of
COVID-19 and other factors, that C3b and C4b degraders are not yet
in human clinical trials and will require additional manufacturing
validation and pre-clinical testing before entering human clinical
trials, the risk that human clinical trial will not replicate the
results of studies in mice or other animals, competition, the
requirement that the Company raise additional capital, and other
risks described in the “Risk Factors” section of the Company’s
Annual Report on Form 10-K filed with the Securities and Exchange
Commission ("SEC") on March 4, 2021, on Form 10-Q filed with the
SEC on August 5, 2021, and in other filings with the SEC. The
forward-looking statements in this presentation represent the
Company's view as of the date of this presentation and the Company
does not assume any obligation to update any forward-looking
statements, except as required by law.
Contact:
Ana KaporCatalyst Biosciences, Inc.investors@catbio.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024